Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Biogen And Sangamo Target Blood Diseases

by Ann M. Thayer
January 20, 2014 | A version of this story appeared in Volume 92, Issue 3

Biogen Idec will work with Sangamo BioSciences on developing treatments for inherited conditions related to the abnormal structure or underproduction of hemoglobin, such as sickle cell disease and β-thalassemia. Sangamo’s zinc finger nuclease genome-editing technology will allow the partners to precisely target and knock out key regulators of gene expression or insert a corrective gene to replace the defective copy. Biogen Idec will pay Sangamo $20 million up front and support R&D. Sangamo could receive another $300 million in milestone payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.